Related Experiment Video
Updated: Jun 8, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Cell cycle arrest in cultured neuroblastoma cells exposed to a bis(thiosemicarbazonato) metal complex
Laura Bica1, Jodi Meyerowitz, Sarah J Parker
1Department of Pathology, The University of Melbourne, Melbourne, VIC 3010, Australia.
Abstract:
Brain tumors such as neuroblastomas and gliomas are often refractory to current treatments. Development of metal-based drugs may offer an alternative approach due to the ability to deliver radionuclides or cytotoxic metals to the tumor. Previous studies have shown that diacetyl-bis(N(4)-methylthiosemicarbazonato)-copper(II) (Cu(II)(atsm)) can selectively target hypoxic tumors and this feature has been utilized for development of imaging and radiotherapy. However, we have recently shown that glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) (Cu(II)(gtsm)) can target the brain in animal models of neurodegeneration. Unlike Cu(II)(atsm), Cu(II)(gtsm) is able to release Cu intracellularly under normoxic conditions. Glyoxal-bis(thiosemicarbazones) have reported anticancer effects but little is known about the cellular mechanisms involved. Therefore, in this study, we used protein microarray analysis to investigate the effect of Cu(II)(gtsm) on neuroblastoma cell growth in vitro. Treatment of the human neuroblastoma cell line BE(2)-M17, resulted in cell cycle arrest as assessed by fluorescent activated cell sorting (FACS) analysis. Rapidly arrested growth was not associated with onset of apoptosis. Instead, protein microarray analysis revealed that Cu(II)(gtsm) rapidly and potently reduced cyclin D1 expression, while increasing Kip2 expression. Other changes observed were decreased Cdk7 expression and activation of CHK2. These changes may be associated with the cell cycle arrest. We also observed a potent decrease of total and phosphorylated insulin-like growth factor receptor (IGF-IR) by Cu(II)(gtsm) which is associated with modulation of cyclin D1 expression. Our studies reveal important insights into the potential anticancer activity of Cu(II)(gtsm). Further studies are needed to examine the therapeutic potential of Cu(II)(gtsm) and other bis(thiosemicarbazonato) metal complexes as metallo-drugs for treatment of systemic or brain tumors.
Insights
Glyoxal-bis(thiosemicarbazonato)-copper(II) (Cu(II)(gtsm)) shows potential as a brain tumor metallo-drug. It effectively halts neuroblastoma cell growth by altering cell cycle proteins like cyclin D1 and IGF-IR.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Brain tumors like neuroblastomas are challenging to treat with current therapies.
- Metal-based drugs offer a promising alternative for targeted cancer treatment.
- Copper(II) bis(thiosemicarbazonato) complexes show potential for cancer therapy.
Purpose of the Study:
- To investigate the in vitro anticancer mechanisms of glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) (Cu(II)(gtsm)) in neuroblastoma cells.
- To identify the specific cellular pathways affected by Cu(II)(gtsm) treatment.
Main Methods:
- Human neuroblastoma BE(2)-M17 cells were treated with Cu(II)(gtsm).
- Cell cycle progression was analyzed using fluorescent activated cell sorting (FACS).
- Protein expression changes were assessed using protein microarray analysis.
Main Results:
- Cu(II)(gtsm) induced cell cycle arrest without triggering apoptosis.
- Key molecular changes included decreased cyclin D1 and Cdk7, increased Kip2, and CHK2 activation.
- The compound significantly reduced insulin-like growth factor receptor (IGF-IR) signaling.
Conclusions:
- Cu(II)(gtsm) exhibits potent anticancer activity against neuroblastoma cells by modulating cell cycle regulatory proteins.
- The observed effects on cyclin D1 and IGF-IR signaling provide insights into its mechanism of action.
- Cu(II)(gtsm) warrants further investigation as a potential metallo-drug for brain tumors.
